Splenic Marginal Zone Lymphoma a Literature Review of Diagnostic and Therapeutic Challenges
Rev Bras Hematol Hemoter. 2017 April-Jun; 39(2): 146–154.
Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges
Received 2016 May 25; Revised 2016 Jul 26; Accepted 2016 Sep nine.
Abstract
Splenic marginal zone lymphoma (SMZL) is a depression-grade B-cell non-Hodgkin'southward lymphoma characterized past massive splenomegaly, moderate lymphocytosis with or without villous lymphocytes, rare involvement of peripheral lymph nodes and indolent clinical grade. Equally a rare disease, with no randomized prospective trials, at that place is no standard of care for SMZL so far. Splenectomy has been washed for many years every bit an attempt to control disease, just nowadays it has not been encouraged as first line considering of new advances in therapy as rituximab, that are every bit effective with minimal toxicity. Facing these controversies, this review highlights advances in the literature regarding diagnosis, prognostic factors, treatment indications and therapeutic options.
Keywords: Lymphoma, non-Hodgkin; Splenic marginal zone lymphoma; Splenic lymphoma; Indolent lymphoma; Rituximab
Introduction and clinical features
Splenic marginal zone lymphoma (SMZL) is a rare indolent non-Hodgkin lymphoma (NHL) subtype that originates from B retention lymphocytes present in the marginal zone of secondary lymphoid follicles.one, 2, 3
Patients usually nowadays massive splenomegaly and bone marrow involvement with minimal or absent lymphadenopathy except for the spleen hilum. In that location is no extranodal interest, except for the bone marrow and liver.three, 4 About 25% of the patients are asymptomatic and the presence of B symptoms or high lactate dehydrogenase levels (LDH) at diagnosis is not usual.5, 6
Lymphocytosis is commonly present. Cytopenias are found in 25% of the cases mostly related to hypersplenism, and less frequently to auto-antibodies or bone marrow infiltration.3, iv
Small-scale amounts (less than 2 yard/dL) of monoclonal protein, usually immunoglobulin (Ig)M kappa, are detected in approximately one third of patients.5, 7 Hyperviscosity syndromes are not usual,3 simply 20% of patients present autoimmune hemolytic anemia and other autoimmune disorders, such every bit thrombocytopenia, cold agglutinin illness, circulating anticoagulants and even angioedema because of acquired C1-esterase inhibitor deficiency.5, seven, viii
The rarity of this disease and its indolent class are a challenge to determine standard care in the treatment and management of patients. There are no randomized trials, near of the literature are retrospective serial of cases from single centers and few prospective studies accept been completed or are ongoing.8
Epidemiology
SMZL is the 2d most mutual subtype of marginal zone lymphoma, comprising about 20% of the cases. It represents near 0.9% of all NHL and was considered a specific pathological entity only in 1991.1, 5, nine
Median age at diagnosis of SMZL is 69 years. The overall age-adapted incidence is 0.13/100,000 habitants per twelvemonth. The percentage change in age-adapted incidence is 4.81%, with nigh of the patients being White.8 Gender prevalence is controversial,half dozen, 7 but there is an increasing trend to male person predominance.8, 10, 11
The association of SMZL with hepatitis C (HCV) is common in the south of Europe,3, 12, thirteen and lymphoma development is normally triggered by the glycoprotein E2 of the virus that stimulates CD81 in B cells.5, half dozen, xiii Although there are controversial data in Brazil regarding the association of HCV and lymphoma, no studies have evaluated this clan.14, 15
The International Lymphoma Epidemiology Consortium Non-Hodgkin Lymphoma Subtypes Project, with a database of 17,471 NHL cases and 23,096 controls, identified an association betwixt SMZL and B cell activating autoimmune conditions, asthma and use of pilus dye.16
Diagnosis
The diagnosis of SMZL tin be past the analysis of pathological cells nowadays in bone marrow with blood and spleen analysis not existence essential.
Bone marrow infiltration is a very common finding (83–100%), although circulating cells are detected much less oft (29–75%).7 During the course of the illness, 75% of the patients will present lymphocytosis, with feature, but non pathognomonic, villous cells.iv, 17 Bone marrow aspirate is not sufficient for diagnosis; a trephine histology with immunohistochemical analysis is required.5
Pathological cells of SMZL are small- to medium-sized mature B cells with circular or oval nuclei and condensed chromatin, basophilic cytoplasm, and well-nigh of the cases present with typical unequal membrane projections (villi), the so-called villous cells (Figure i).4, five, vi, seven Marrow infiltration tin be nodular, interstitial or intrasinusoidal.v
Morphologic features of villous lymphocytes in patients with splenic marginal zone lymphoma.
In that location is no specific immunophenotypic blueprint for SMZL. Pathological cells are usually positive for CD19, CD20, CD22, CD79a, CD79b, FMC7 and IgM and negative for CD5, CD10, CD43, BCL6, cyclin D1 or CD103. The expressions of CD23, IgD and cytoplasmatic Ig are variable,half dozen, 18 usually scoring 0–2 points in the Modified Matutes scoring organisation.19 CD5 are weakly positive in 10–25% of the cases, even with the co-expression of CD23 or CD43.20 CD11c and CD25 are sometimes positive, but CD103 and CD123 are near always negative.4
Bone marrow immunohistochemistry analysis reveals positivity for CD45RA, CD45RB, CD19, CD20, CD79a, PAX5/BSAP, IgD, Bcl-ii, DBA-44 (CD72), TRAP and CD38.v, 21, 22 IgM is normally brilliant, just IgD is variable.4, six Cells are normally negative for CD3, CD5, CD10, CD23, CD43, cyclin D1, anexin-A1 and BCL6. KI67/Mib1 has a low proliferation index with a characteristic pattern.four, vi
The spleen is frequently enlarged, with a median weight of 1750 yard (270–5500 m) and many grayish nodules throughout the parenchyma.6 White pulp is expanded by neoplastic cells that environment and eventually substitute germinal centers. Nodules are composed of pathological cells, located in an inner zone of small- to medium-sized B cells with circular nuclei, clumped chromatin and scanty cytoplasm. Externally there is an outer zone with medium-sized pathological cells, with more irregular nucleus outlines, dispersed chromatin and moderately clear cytoplasm. In that location are scattered cells in this zone resembling immunoblasts. As the illness progresses, the central germinal centre becomes effaced. The ruby-red pulp is invariably enveloped to a varying degree past pocket-sized aggregates of larger cells and sheets of small cells, which often occupy sinuses and cords. There tin exist epithelioid granulomas and plasmacytic differentiation, the former especially when at that place is a monoclonal serum component. Immunohistochemical findings are similar to bone marrow findings.five, vi, 9
Matutes et al. proposed minimum diagnostic criteria for SMZL:
-
a)
When spleen pathology is available: spleen histology and immunophenotype with a modified Matutes score of <3 points.19
-
b)
When the patient has clinical splenomegaly and splenectomy is not performed, it is sufficient to make the diagnosis with typical blood and bone marrow findings past morphology and immunophenotype with intrasinusoidal infiltration by CD20+ cells.
After the diagnosis is performed, information technology is important to evaluate the clinical phase of the patient, with computed tomography scans and routine exams to discover comorbidities that may affect the choice of handling. These exams should include complete blood count with differential, serologic tests for hepatitis B and C and human immunodeficiency virus (HIV), renal and liver role tests, serum calcium, LDH, and b2-microglobulin. SMZL is regarded every bit a none F-18 fluorodeoxyglucose-avid disease; thus, the use of fluorodeoxyglucose positron emission tomography (FDG-PET) should exist discouraged in the staging process.23
Differential diagnosis
The differential diagnosis requires the joint analysis of clinical, morphological, immunophenotypic and genetic data, as well as immunohistochemistry.5, vi
Reactive follicular hyperplasia and other small B cell lymphomas should be excluded, as the blueprint of splenic micronodular involvement of marginal zone differentiation and the villous lymphocytes in peripheral claret are non pathognomonic.four
A diagnostic test should not be performed on spleens weighing less than 300–400 g or in the absence of a standard monotypic pattern.eight
CD43 and CD200 positivity and a high (three–5) modified Matutes score helps to differentiate between SMZL and chronic lymphocytic leukemia.nineteen Intrasinusoidal infiltration is unusual in chronic lymphocytic leukemia, just ofttimes seen in SMZL, in hairy jail cell leukemia variant (LCP-5) and sometimes in mantle jail cell lymphoma (MCL).five In rare cases of SMZL, CD5+, morphology, negativity for cyclin D1 and SOX11, and absenteeism of t(11;fourteen) excludes MCL.
Hairy prison cell leukemia (HCL) subtypes involving the spleen are distinguished by their characteristic morphology and phenotype. CD103 and CD123 negativity exclude HCL.4
Unlike SMZL, nodules have variable sizes and tumoral cells are seen in white pulp in the example of follicular lymphoma (FL). CD10 and BCL6 expression are useful for the diagnosis of FL. The morphological characteristics of the MIB 1 tumor cell staining pattern, residual mantle cell, IgD staining for tumor cells in addition to histological findings in bone marrow and hilar lymph nodes help establish diagnosis.5
Differential diagnosis between SZML, splenic diffuse red pulp lymphoma (SDRPL) and HCL-v tin exist tricky and sometimes impossible only by blood or bone marrow analyses. These are two newly recognized entities with clinicopathologic and immunophenotypic features partially overlapping those of SMZL. The diagnosis in these cases requires detailed clinical data, a comprehensive phenotype and spleen histology, which usually shows a typical pattern of diffuse infiltration with white pulp follicles preserved.eight
An immunophenotypic contour with the absence of CD25, CD123, interleukin-three anti-receptor, annexin A1, HC2 and TRAP and resistance to conventional HCL therapy is observed for HCL-five.6, 24, 25 Moreover, HCL-five is positive for the DBA-44, pan-B cells, CD11c, surface monotypic Ig (IgG most oftentimes) and CD103 FMC7.v, 9
Although SDRPL have characteristics that overlap classic SMZL, the expression of IgD and the follicular micronodular pattern is absent in most cases.5 The distinction betwixt those two entities may be merely academic, as the treatment is not different.26
Lymphoplasmacytic lymphoma (LPL) may develop in the spleen, with homogeneous infiltration of the white lurid without standard marginal zone and monocytoid B cells. Deletions of 7q, 3T gains and intrasinusoidal infiltration are characteristic of SMZL, while del(6q) is more characteristic of LPL.27 Another useful marking is the MYD88 L265P mutation, that is frequent in LPL (91–100%) and rare in SMZL (half-dozen%).28
Moreover, there are overlapping patterns of extranodal marginal zone lymphoma (EMZL) and SMZL with the clinical findings being crucial for differentiation. Splenic involvement is rare in nodal marginal zone lymphoma (NMZL) and Immunoglobulin Superfamily Receptor Translocation Associated 1 (IRTA1), negative in 76% of SMZL, is positive in NMZL.24 Two useful features to distinguish between SMZL and mucosa-associated lymphoid tissue (MALT) are the absenteeism of the t(11;xviii)(q21;q21)29 and the frequent IgD expression in SMZL, which is rarely observed in MALT lymphoma.5, 30
Prognosis
Although virtually of the cases of SMZL have an indolent form with median overall survival of about ten years,eighteen, 22 about thirty% of the patients develop ambitious disease, with median overall survival of only 4 years.x, 18 There are no associated cytogenetic features31 and prognostic scores for indolent lymphomas such as the International Prognostic Index (IPI)xviii, 32 and Follicular International Prognostic Index (FLIPI)33 are not applicable. The same can exist said for the Ann Arbor staging system, which is not adequate because in almost cases the bone marrow is involved.34
There are some clinical features associated with a worse outcome such every bit the development of lymphadenopathy, increase in β2-microglobulin, not-hematopoietic site involvement, leukocyte count >20 × 109/50, lymphocytosis >9 × 109/L, lymphopenia, anemia, thrombocytopenia, utilise of chemotherapy, monoclonal component, performance status ≥2, incomplete response, advanced historic period, diffuse pattern of bone marrow infiltration and histologic transformation.8, 10, 35, 36, 37, 38
Many karyotype abnormalities can be institute: trisomy 3q (85%) del or translocation of 7q32 (forty%), trisomy eighteen, 17q isochromosome, 13q14 deletion, and structural abnormalities of chr 1.39 Some molecular aspects, such as NOTCH2 and KLF2 mutations, Ig factor mutation status, TP53 abnormalities and aberrant promoter methylation seem to be related to a worse outcome.31, 37, 40, 41 Studies from a whole exome sequencing study identified the MYD88 L265P missense mutation in 15% of SMZL.42
The Italian Intergroup for Lymphomas (IIL), now Fondazione Italiana Linfomi (FIL) adult the first prognostic score later a multicenter trial with 309 patients. Specific upshot survival (SES) related to death by lymphoma was analyzed, every bit was overall survival. The 5-year cause-specific survival rate was 76%. The three almost important parameters in multivariate assay were hemoglobin <12 g/dL, LDH higher than normal and depression albumin (<3.5 chiliad/dL). Patients were grouped in three categories co-ordinate to 0, 1 or 2–iii parameters, respectively, low chance (41% of the cases, five-year SES of 88%), intermediate risk (34% of the cases, 5-year SES of 73%) and high risk (25% of the cases, 5-yr SES of 50%).18 A recent report by Perrone et al. validated the score.26
In 2012, the Hemoglobin-Platelet-LDH-actress-hilar-Lymphadenopathy (HPLL) score was proposed by the SMZL Study Grouping subsequently a retrospective analysis of 593 patients. Patients were stratified in 3 groups as shown in Table 1. The criteria of the IIL were applied to the same population but the stratification power for SES of the HPLL score were better,43, 44 so this seems to be the about suitable score so far.
Table one
Hemoglobin-platelet-LDH-extra-hilar-lymphadenopathy score for splenic marginal zone lymphoma equally proposed past the Splenic Marginal Zone Lymphoma Study Group.
| Stratification | ||
|---|---|---|
| Take chances group | Specific event survival | |
| A | No adverse genea | 95% |
| B | 1–ii adverse factorsa | 87% |
| C | three–iv adverse factorsa | 68% |
Indication for treatment
There are no standard criteria to signal treatment. The overall survival of asymptomatic patients tin can be as high as 88% at 5 years without treatment23.
Tarella et al.,23 proposed some criteria to indicate handling (Table 2).
Table two
Criteria to indicate treatment of splenic marginal zone lymphoma.
| Progressive or symptomatic splenomegaly |
| Cytopenias: |
| Hemoglobin < ten thou/dL or |
| Neutrophils < i × 109/L |
| Progressive thrombocytopenia |
| Constitutional symptoms |
| Progressive nodal illness |
| Autoimmune hemolytic anemia |
The SMZL Report Grouping too considered low hemoglobin levels, extranodal affliction and a positivity for HCV as important to indicate treatment even though these factors take not been validated nonetheless.44
A recent report by Perrone et al. suggested that patients should undergo an evaluation of the tumor brunt like to follicular patients, but this awaits further validation.26
Types of treatment
As a rare affliction with an indolent course, determining the standard treatment and direction is a challenge as at that place have been no randomized trials and most reports are of unmarried-eye serial of retrospective cases; few prospective trials take been completed or are ongoing.viii Therefore, nowadays there is no standard care for SMZL.
Therapeutic options for SMZL comprise splenectomy, chemotherapy and the use of the anti-CD20 monoclonal antibody rituximab alone or in chemotherapy combinations.35, 45, 46, 47, 48, 49, 50, 51, 52
Splenectomy
Splenectomy was the therapy of choice for decades and is nonetheless frequently used, although there is a tendency to prescribe rituximab monotherapy upfront, as most patients are erstwhile and with co-morbidities.10, xi, 52, 53, 54 Laparoscopy should be preferred whenever possible in patients with avant-garde age or comorbidities.8
Although marrow interest is non treated, splenectomy allows quick remission of the symptoms of hypersplenism and cytopenias, such as a significant reduction of circulating lymphocytes in xc% of patients. Regarding clinical improvement, in a series written report, seven patients (25%) had increases in os marrow infiltration by pathological cells, there was a modification of the pattern in five of them.
The median overall survival in most series is near ten years and seventy% of the patients can remain handling free for five years.17, 36, 53 At that place is no survival do good for the association of chemotherapy with splenectomy,17 although some studies written report increases in overall response rates.47 Tabular array 3, Tabular array four summarize the studies regarding dissimilar types of therapy for SMZL.
Table three
Splenic marginal zone lymphoma patients treated with splenectomy.
| Reference | Yr | due north | ORR (%) | Response | Expiry due to surgery | |
|---|---|---|---|---|---|---|
| Duration | Os | |||||
| Mulligan et al. | 1991 | 20 | 95 | Median DOR 4 years | NR | 1 |
| Troussard et al. | 1996 | 28 | 75 | NR | 71% at 5 years | ane |
| Chacón et al. | 2002 | lxa | 93.3 | Median FFS twoscore months | 65% at 5 years | NR |
| Thieblemont et al. | 2002 | 48b | 100 | PFS 48% at 5 years | NR | NR |
| Parry-Jones et al. | 2003 | 33 | NR | NR | LSS 95% at 10 years | NR |
| Iannitto et al. | 2004 | 21 | 91 | Median DOR 4 y | NR | NR |
| Tsimberidou et al. | 2006 | ten | 60 | FFS 80% at iii years | 89% at 3 years | 0 |
| Olszewski et al. | 2012 | 652 | NR | NR | 67.8% at 5 yearsc | NR |
| Kalpadakis et al. | 2013 | 27 | 85 | PFS 58% at v years | 77% at 5 years | one |
| Lenglet et al. | 2014 | 100 | 97 | PFS 61% at 5 y | 84% at 5 years | 0 |
| Xing et al. | 2015 | 52d | NR | FFS 39% at 10 years | 61% at x years | 0 |
| Pata et al. | 2015 | 41 | xc | PFS 35% at 5 years | 75% at 5 years | 0 |
Table four
Splenic marginal zone lymphoma patients treated with rituximab-based regimens.
| Reference | Year | Written report type | Regimen | Patient status | n | ORR (%) | Response | |
|---|---|---|---|---|---|---|---|---|
| Elapsing | OS | |||||||
| Rituximab monotherapy | ||||||||
| Bennett et al. | 2005 | Retrospective | R monotherapy | RR | xi | 91% | PFS sixty% at 5 years | lxx% at 5 years |
| Tsimberidou et al. | 2006 | Retrospective | R monotherapy | First line | 25 | 88% | FFS 86% at 3 years | 95% at 3 years |
| Kalpadakis et al. | 2007 | Retrospective | R monotherapy | First line | sixteen | 100% | PFS 92% at 2.four years | 100% at ii.1 years |
| Else et al. | 2012 | Retrospective | R monotherapy | First line and RR | 10 | 100% | DFS 89% at 3 years | NR |
| Kalpadakis et al. | 2013 | Retrospective | R monotherapy | Beginning line | 58 | 95% | PFS 73% at 5 years | 92% at 5 years |
| Rituximab+Chemotherapy | ||||||||
| Tsimberidou et al. | 2006 | Retrospective | R-chemo | Kickoff line | half dozen | 83% | FFS 100% at three years | 100% at 3 years |
| Else et al. | 2012 | Retrospective | R-chemo | First line and RR | 33 | 100% | DFS 71% at 3 years | NR |
| Cervetti et al. | 2013 | Retrospective | R-2CDA | First line and RR | 47a | 87% | PFS 80% at 5 years | 86% at 5 years |
| Iannitto et al. | 2015 | Prospective | R-COMP | Kickoff line | 51 | 84% | PFS 54% at vi years | 72% at 6 years |
Pata et al. reported perioperative complications in one quarter of 41 patients submitted to splenectomy as starting time-line handling: 8 cases (19.5%) of pulmonary dysfunction, i case (ii.4%) of deep vein thrombosis, 1 case (ii.iv%) of portal vein thrombosis and nine cases (22%) of major bleeding.55
Infections caused by encapsulated leaner are the major risk associated with splenectomy and vaccination against capsulated bacteria is mandatory at least two weeks before elective splenectomy.8
Splenectomy should not be performed if the patient has nodal interest outside the splenic hilum and, conversely, it should not be omitted in cases with suspected transformation.8
Chemotherapy
Alkylating agents and purine analogs accept been used every bit have many chemotherapy combinations such as cyclophosphamide, vincristine and prednisone (CVP); cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), and fludarabine and cyclophosphamide (FC).35, 45, 46, 47, 48, 49, fifty, 51 About two-thirds of patients do not reply to starting time-line treatment with chorambucil.half dozen
Rituximab monotherapy
Rituximab every bit monotherapy is effective in SMZL with results like to splenectomy; information technology has the potential to provide meliorate responses and has less toxicity compared to chemotherapy.8 Rituximab has niggling impact on the quality of life, has reduced run a risk of infections, seems to induce durable remissions and can be used again at relapse.46, 49, fifty, 56 Clinical and laboratorial responses are fast, with improvement in blood counts in about eight weeks.57
Some studies report inferior outcomes of rituximab monotherapy compared to splenectomy, only in non-randomized retrospective clinical trials in that location may be a bias of selecting younger and fitter patients for splenectomy (Table 3).8
Kalpadakis et al. reported a retrospective study of 58 patients treated with rituximab 375 mg/m2 in an induction phase (weekly for half-dozen weeks) followed by a maintenance phase with rituximab every ii months for one to two years. The complete response (CR) rate afterwards the induction phase was 45%, unconfirmed CR was 26% and partial response was 24%. The 5-year overall survival and progression-free survival were 92% and 73%, respectively (p-value <0.001)46. At that place are other regimens using rituximab; weekly for four weeks with or without maintenance as reported by Bennet et al.58 The best regimen, whether to utilise maintenance or retreatment at relapse, is also areas that need to be clarified.
Rituximab with chemotherapy
The aforementioned chemotherapy options are used alone or with rituximab. Purine analogs are more toxic and should be reserved for refractory or relapsed cases. Fludarabine has high response rates, with CR in 70% of cases and progression-gratis survival of 4.seven years.57, 58 A combination with Cladribine increased the CR from 21.4% to 62.5%, and 4-year progression-free survival from 52.4% to 83.iv%.51
There are no results from randomized trials specific for SMZL, but at that place are some ongoing studies, such as the BRISMA stage II trial with Bendamustin plus rituximab, {"type":"clinical-trial","attrs":{"text":"NCT01332968","term_id":"NCT01332968"}}NCT01332968 with obinutuzumab plus CHOP/CVP/BR, ibrutinib ({"type":"clinical-trial","attrs":{"text":"NCT01980628","term_id":"NCT01980628"}}NCT01980628 and {"type":"clinical-trial","attrs":{"text":"NCT01974440","term_id":"NCT01974440"}}NCT01974440), and PI3K inhibitors ({"type":"clinical-trial","attrs":{"text":"NCT01282424","term_id":"NCT01282424"}}NCT01282424, {"type":"clinical-trial","attrs":{"text":"NCT01732926","term_id":"NCT01732926"}}NCT01732926, {"type":"clinical-trial","attrs":{"text":"NCT02369016","term_id":"NCT02369016"}}NCT02369016, {"blazon":"clinical-trial","attrs":{"text":"NCT02367040","term_id":"NCT02367040"}}NCT02367040, and {"type":"clinical-trial","attrs":{"text":"NCT01732913","term_id":"NCT01732913"}}NCT01732913) (Table 4).
Treatment of patients with splenic marginal zone lymphoma and hepatitis C
Patients with hepatitis C who practise not require an firsthand cytoreductive treatment should receive commencement-line antiviral handling with pegylated blastoff-interferon and ribavirin, considering a CR of SMZL occurs in well-nigh 75% of the cases.39, 59
Splenic irradiation
Splenic irradiation has historical interest and there are isolated reports of its use before the era of rituximab therapy.21, threescore
Handling considerations
Arcaini et al. proposes a consensus using the guidelines of both the European Society for Medical Oncology39 and the Società Italiana di Ematologia.23 According to the European Lodge, rituximab monotherapy is a reasonable kickoff-line therapy and a less traumatic culling to splenectomy and according to the Italian Society, rituximab is a skillful option for patients without disseminated disease (no lymphadenopathy other than spleen hilum, no constitutional symptoms or signs of high-grade transformation) who need treatment and are non eligible for splenectomy. The group of patients with constitutional symptoms or signs of high-grade transformation may be eligible for rituximab-chemotherapy combinations. There is no standard care so far, but combinations with CVP and chlorambucil are accepted as showtime line.23
Figure 2 illustrates a suggested algorithm for the treatment of SMZL patients based on these guidelines.
Suggested approach to treat splenic marginal zone lymphoma.
Response evaluation
The criteria used to evaluate response of patients with SMZL to treatment are shown in Table 5.
Table 5
Response criteria for splenic marginal zone lymphoma.
| Complete response | • Resolution of organomegaly (spleen longitudinal diameter < thirteen cm). • Hemoglobin >12 chiliad/dL, platelets >100 × x9/L, and neutrophils >1.5 × 10nine/L. • No evidence of circulating clonal B cells by flow cytometry (low-cal chain restricted B cells). • No evidence of os marrow infiltration detected past immunohistochemistry. • Optional: negative direct antiglobulin exam (DAT) and normal positron emission tomography (PET) scan (if positive at diagnosis). |
| Partial response | • Regression of ≥fifty% in all the measurable disease manifestations. • No new sites of affliction. • Comeback of cytopenias. • Subtract of infiltration and improvement of hematopoietic reserve at bone marrow biopsy. |
| No response | • <ten% comeback of the disease manifestations. |
| Progression | • >fifty% of measurable signs of the illness from nadir. |
| Relapse | • Re-appearance of whatsoever measurable sign of the disease. |
Follow-up
Asymptomatic patients should be seen every half dozen months with no more than a physical examination, claret counts, and biochemistry. The interval betwixt visits should exist shortened in cases of increasing splenomegaly or the occurrence of cytopenia. Computed tomography and bone marrow biopsy are non indicated unless signs of disease progression are identified.39
During the starting time three months of treatment, claret counts and laboratory piece of work-ups should be performed every four to half dozen weeks and every six months thereafter.39
Last considerations
SZML is an indolent lymphoma that presents many unsolved questions, such every bit standard prognostic criteria and standard treatment. As it comprises less than two% of lymphomas, big randomized clinical trials are not likely and review articles that clarify some issues are important in the clinical practice.
Conflicts of interest
The authors declare no conflicts of interest.
References
i. Zinzani P.L. The many faces of marginal zone lymphoma. ASH Educ Progr B. 2012;2012(1):426–432. [PubMed] [Google Scholar]
2. Lenglet J., Traullé C., Mounier N., Benet C., Munoz-Bongrand N., Amorin Due south. Long-term follow-up assay of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line handling. Leuk Lymphoma. 2013;55:1854–1860. [PubMed] [Google Scholar]
3. Swerdlow S.H., Campo E., Harris North.L., Jaffe E.S., Pileri South.A., Stein H. In: World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Swerdlow South.H., Campo E., Harris N.50., Jaffe Eastward.S., Pileri S.A., Stein H., et al., editors. International Agency for Research on Cancer (IARC); Lyon: 2008. International Bureau for Research on Cancer (IARC). 422 p. [Google Scholar]
iv. Behdad A., Bailey N.G. Diagnosis of splenic B-prison cell lymphomas in the bone marrow: a review of histopathologic, immunophenotypic, and genetic findings. Arch Pathol Lab Med. 2014;138(x):1295–1301. [PubMed] [Google Scholar]
5. Matutes Eastward., Oscier D., Montalban C., Berger F., Callet-Bauchu E., Dogan A. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487–495. [PubMed] [Google Scholar]
6. Mendes Fifty.Due south., Du M.-Q., Matutes E., Wotherspoon A. Splenic marginal zone lymphoma: a review of the clinical presentation, pathology, molecular biology, and direction. Blood Lymph Cancer: Targets Therapy. 2014;iv:29–38. [Google Scholar]
vii. Traverse-Glehen A., Baseggio L., Salles G., Felman P., Berger F. Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification. Curr Opin Oncol. 2011;23(v):441–448. [PubMed] [Google Scholar]
8. Arcaini L., Rossi D., Paulli M. Splenic marginal zone lymphoma: from genetics to direction. Blood. 2016;127(17):2072–2081. [PubMed] [Google Scholar]
nine. Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe East.S. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. 2011;117(19):5019–5032. [PMC free article] [PubMed] [Google Scholar]
10. Chacón J.I., Mollejo M., Muñoz E., Algara P., Mateo G., Lopez L. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100(5):1648–1654. [PubMed] [Google Scholar]
11. Iannitto E., Ambrosetti A., Ammatuna E., Colosio M., Florena A.M., Tripodo C. Splenic marginal zone lymphoma with or without villous lymphocytes. Cancer. 2004;101(ix):2050–2057. [PubMed] [Google Scholar]
12. Arcaini L., Merli M., Volpetti S., Rattotti S., Gotti M., Zaja F. Indolent B-prison cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin Dev Immunol. 2012;2012:1–10. [PMC gratuitous article] [PubMed] [Google Scholar]
xiii. Tasleem Due south., Sood Yard.K. Hepatitis C associated B-cell non-hodgkin lymphoma: clinical features and the role of antiviral therapy. J Clin Transl Hepatol. 2015;3(2):134–139. [PMC costless article] [PubMed] [Google Scholar]
xiv. Marinho T.A. Universidade Federal de Goiás; 2013. Prevalência da infecção pelo vírus da hepatite C em indivíduos portadores de doenças oncohematológicas em Goiânia-GO. [Google Scholar]
xv. Chindamo M., Spector N., Segadas J., Pimenta Yard., Vanderborght B., Morais J. Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphomas. Oncol Rep. 2002;9(8):657–659. [PubMed] [Google Scholar]
xvi. Bracci P.M., Benavente Y., Turner J.J., Paltiel O., Slager S.50., Vajdic C.G. Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the interlymph non-Hodgkin lymphoma subtypes project. JNCI Monogr. 2014;2014(48):52–65. [PMC complimentary commodity] [PubMed] [Google Scholar]
17. Vannata B., Stathis A., Zucca East. Management of the marginal zone lymphomas. In: Evens A.M., Blum Thousand.A., editors. Non-Hodgkin lymphoma. Springer International Publishing; Cham: 2015. pp. 227–249. (Cancer Treatment and Research; vol. 165) [Google Scholar]
18. Arcaini L., Lazzarino M., Colombo N., Burcheri S., Boveri E., Paulli Thousand. Splenic marginal zone lymphoma: a prognostic model for clinical employ. Blood. 2006;107(12):4643–4649. [PubMed] [Google Scholar]
19. Moreau E.J., Matutes East., A'Hern R.P., Morilla A.M., Morilla R.1000., Owusu-Ankomah K.A. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8(CD79b) Am J Clin Pathol. 1997;108(4):378–382. [PubMed] [Google Scholar]
20. Evens A.Grand., Blum M.A. Cancer Handling and Research; Switzerland: 2015. Non-Hodgkin lymphoma. 343 p. [Google Scholar]
21. Troussard Ten., Valensi F., Duchayne E., Garand R., Felman P., Tulliez M. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a serial of 100 patients. Br J Haematol. 1996;93(3):731–736. [PubMed] [Google Scholar]
22. Salomon-Nguyen F., Valensi F., Troussard X., Flandrin Thou. The value of the monoclonal antibody, DBA44, in the diagnosis of B-lymphoid disorders. Leuk Res. 1996;xx(xi/12):909–913. [PubMed] [Google Scholar]
23. Tarella C., Arcaini L., Baldini L., Barosi Thou., Billio A., Marchetti M. Italian order of hematology, italian society of experimental hematology, and italian grouping for bone marrow transplantation guidelines for the management of indolent, nonfollicular b-jail cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic) Clin Lymphoma Myeloma Leuk. 2015;15(two):75–85. [PubMed] [Google Scholar]
24. Falini B., Agostinelli C., Bigerna B., Pucciarini A., Pacini R., Tabarrini A. IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology. 2012;61(v):930–941. [PubMed] [Google Scholar]
25. Venkataraman Yard., Aguhar C., Kreitman R.J., Yuan C.M., Stetler-Stevenson M. Feature CD103 and CD123 expression pattern defines hairy prison cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am J Clin Pathol. 2011;136(four):625–630. [PMC complimentary article] [PubMed] [Google Scholar]
26. Perrone S., D'Elia G.K., Annechini G., Ferretti A., Tosti Yard.E., Foà R. Splenic marginal zone lymphoma: prognostic factors, office of sentry and wait policy, and other therapeutic approaches in the rituximab era. Leuk Res. 2016;44:53–60. [PubMed] [Google Scholar]
27. Schop R.F. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002;100(eight):2996–3001. [PubMed] [Google Scholar]
28. Treon S.P., Hunter Z.R. A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Claret. 2013;121(22):4434–4436. [PubMed] [Google Scholar]
29. Remstein E.D., James C.D., Kurtin P.J. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol. 2000;156(4):1183–1188. [PMC costless article] [PubMed] [Google Scholar]
xxx. Du M.Q., Peng H.Z., Dogan a, Diss T.C., Liu H., Pan L.X. Preferential dissemination of B-jail cell gastric mucosa-associated lymphoid tissue (MALT) lymphoma to the splenic marginal zone. Claret. 1997;90(10):4071–4077. [PubMed] [Google Scholar]
31. Salido G., Baro C., Oscier D., Stamatopoulos Yard., Dierlamm J., Matutes E. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Grouping. Blood. 2010;116(9):1479–1488. [PubMed] [Google Scholar]
32. Federico Grand., Vitolo U., Zinzani P.Fifty., Chisesi T., Clò V., Bellesi G. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood. 2000;95(3):783–789. [PubMed] [Google Scholar]
33. Solal-Celigny P., Roy P., Colombat P., White J., Armitage J.O., Arranz-Saez R. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265. [PubMed] [Google Scholar]
34. Carbone P.P., Kaplan H.S., Musshoff Chiliad., Chairman P.P., Smithers D.Due west., Tubiana M. Report of the Committee on Hodgkin'due south Illness Staging Classification Study of the Committee on Hodgkin's Illness Staging Nomenclature. Cancer Res. 1971;31(eleven):1860–1861. [PubMed] [Google Scholar]
35. Tsimberidou A.M., Catovsky D., Schlette E., O'Brien S., Wierda W.G., Kantarjian H. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy lone. Cancer. 2006;107(1):125–135. [PubMed] [Google Scholar]
36. Thieblemont C., Davi F., Noguera M-Eastward., Brière J., Bertoni F., Zucca E. Splenic marginal zone lymphoma: current knowledge and futurity directions. Oncology (Williston Park) 2012;26(2):194–202. [PubMed] [Google Scholar]
37. Hockley Southward.Fifty., Else M., Morilla A., Wotherspoon A., Dearden C., Catovsky D. The prognostic impact of clinical and molecular features in hairy jail cell leukaemia variant and splenic marginal zone lymphoma. Br J Haematol. 2012;158(3):347–354. [PubMed] [Google Scholar]
38. Matutes E. Splenic marginal zone lymphoma: disease features and management. Expert Rev Hematol. 2013;half-dozen(six):735–745. [PubMed] [Google Scholar]
39. Dreyling M., Thieblemont C., Gallamini A., Arcaini 50., Campo Due east., Hermine O. Esmo consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, curtain jail cell lymphoma, peripheral T-jail cell lymphoma. Ann Oncol. 2013;24(iv):857–877. [PubMed] [Google Scholar]
xl. Parry M., Rose-Zerilli M.J.J., Ljungstrom 5., Gibson J., Wang J., Walewska R. Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res. 2015;21(18):4174–4183. [PMC free article] [PubMed] [Google Scholar]
41. Gruszka-Westwood A.M. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood. 2001;97(11):3552–3558. [PubMed] [Google Scholar]
42. Peveling-Oberhag J., Wolters F., Döring C., Walter D., Sellmann L., Scholtysik R. Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations. BMC Cancer. 2015;15(1):773. [PMC free article] [PubMed] [Google Scholar]
43. Montalbán C., Abraira V., Arcaini Fifty., Domingo-Domenech Due east., Guisado-Vasco P., Iannitto E. Simplification of risk stratification for splenic marginal zone lymphoma: a bespeak-based score for applied use. Leuk Lymphoma. 2014;55(iv):929–931. [PubMed] [Google Scholar]
44. Montalbán C., Abraira V., Arcaini Fifty., Domingo-Domenech Due east., Guisado-Vasco P., Iannitto E. Chance stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, loftier lactate dehydrogenase level and extrahilar lymphadenopathy: evolution and validation on 593 cases. Br J Haematol. 2012;159(2):164–171. [PubMed] [Google Scholar]
45. Thieblemont C., Felman P., Berger F., Dumontet C., Arnaud P., Hequet O. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002;three(1):41–47. [PubMed] [Google Scholar]
46. Kalpadakis C., Pangalis 1000.A., Maria M.A., Sachanas Due south., Kontopidou F.N., Yiakoumis X. Handling of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist. 2013;eighteen(2):190–197. [PMC free article] [PubMed] [Google Scholar]
47. Else M., Marín-Niebla A., de la Cruz F., Batty P., Ríos E., Dearden C.Eastward. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol. 2012;159(3):322–328. [PubMed] [Google Scholar]
48. Iannitto Eastward., Tripodo C. How I diagnose and treat splenic lymphomas. Blood. 2011;117(ix):2585–2595. [PubMed] [Google Scholar]
49. Bennett M., Schechter G.P. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol. 2010;47(2):143–147. [PubMed] [Google Scholar]
fifty. Kalpadakis C., Pangalis Yard.A., Vassilakopoulos T.P., Sachanas S., Kyrtsonis K.C., Dimopoulou M. Splenectomy versus Rituximab in the treatment of splenic marginal zone lymphoma. Haematologica. 2009;94(Suppl. 2):168–169. [Google Scholar]
51. Cervetti G., Galimberti S., Pelosini M., Ghio F., Cecconi N., Petrini Thou. Significant efficacy of two-chlorodeoxyadenosine + rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. Ann Oncol. 2013;24(9):2434–2438. [PubMed] [Google Scholar]
52. Kalpadakis C., Pangalis Chiliad.A., Vassilakopoulos T.P., Sachanas South., Angelopoulou M.G. Handling of splenic marginal zone lymphoma: should splenectomy be abandoned? Leuk Lymphoma. 2014;55(7):1463–1470. [PubMed] [Google Scholar]
53. Parry-Jones N., Matutes E., Gruszka-Westwood A.M., Swansbury K.J., Wotherspoon A.C., Catovsky D. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003;120(v):759–764. [PubMed] [Google Scholar]
54. Lenglet J., Traull C., Mounier Northward., Benet C., Munoz-bongrand N., Amorin Southward. Long-term follow-up assay of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line handling. Leuk Lymphoma. 2014;55(8):1854–1860. [PubMed] [Google Scholar]
55. Pata Thou., Damiani E., Bartoli Yard., Solari Due south., Anastasia A., Pagani C. Peri-operative complications and hematologic improvement later on starting time-line splenectomy for splenic marginal zone lymphoma. Leuk Lymphoma. 2016;57(6):1467–1470. [PubMed] [Google Scholar]
56. Olszewski A.J., Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. Ann Hematol. 2014;93(3):449–458. [PubMed] [Google Scholar]
57. Kalpadakis C., Pangalis G.A., Dimopoulou One thousand.N., Vassilakopoulos T.P., Kyrtsonis M-C., Korkolopoulou P. Rituximab monotherapy is highly constructive in splenic marginal zone lymphoma. Hematol Oncol. 2007;25(3):127–131. [PubMed] [Google Scholar]
58. Bennett M., Yegena S., Chubar E., Schechter G. Rituximab monotherapy in splenic marginal zone lymphoma instead of splenectomy. Br J Haematol. 2010;149(Suppl. 1):45. [Google Scholar]
59. Arcaini L., Vallisa D., Rattotti South., Ferretti V.5., Ferreri A.J., Bernuzzi P. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a report of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(vii):1404–1410. [PubMed] [Google Scholar]
60. El Weshi A., Ribrag V., Girinski T., El Hajj M., Dhermain F., Bayle C. Low and medium dose spleen radiation therapy are able to induce long-term responses in splenic lymphoma with villous lymphocytes. Br J Haematol. 1998;103(4):1212–1213. [PubMed] [Google Scholar]
Articles from Revista Brasileira de Hematologia eastward Hemoterapia are provided here courtesy of Sociedade Brasileira de Hematologia east Hemoterapia
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457460/
0 Response to "Splenic Marginal Zone Lymphoma a Literature Review of Diagnostic and Therapeutic Challenges"
Post a Comment